Literature DB >> 25188431

Early clinical experience with digital breast tomosynthesis for screening mammography.

Melissa A Durand1, Brian M Haas, Xiaopan Yao, Jaime L Geisel, Madhavi Raghu, Regina J Hooley, Laura J Horvath, Liane E Philpotts.   

Abstract

PURPOSE: To examine recall rates from screening mammography and the mammographic findings that caused recall in women who underwent digital breast tomosynthesis with conventional mammography (referred to as two-dimensional [ 2D two-dimensional ] with three-dimensional [ 3D three-dimensional ] imaging [ 2D two-dimensional + 3D three-dimensional ]) and in women who underwent conventional mammography alone (referred to as 2D two-dimensional ).
MATERIALS AND METHODS: This was an institutional review board-approved, HIPAA-compliant study with waivers of informed consent. A retrospective review of 2D two-dimensional + 3D three-dimensional and 2D two-dimensional screening mammograms from August 1, 2011, to December 31, 2012, was performed. Recall rates and abnormalities that caused recall were compared by controlling for differences in patient age, breast density, and risk factors. Cancer detection rate was assessed from this time period and from 1 year before the introduction of tomosynthesis for a historic control.
RESULTS: This study included 17 955 screening mammograms; of the total, there were 8591 (47.8%) 2D two-dimensional + 3D three-dimensional screening examinations and 9364 (52.2%) 2D two-dimensional examinations. The recall rate was 7.8% (671 of 8592) for 2D two-dimensional + 3D three-dimensional and 12.3% (1154 of 9364) for 2D two-dimensional (P < .0001); the rate of recall was 36.6% lower in the 2D two-dimensional + 3D three-dimensional group than in the 2D two-dimensional group. Recall rates for the 2D two-dimensional + 3D three-dimensional group were significantly lower for patients with asymmetries, ( 2D two-dimensional + 3D three-dimensional vs 2D two-dimensional , 3.1% [267 of 8591] vs 7.4% [689 of 9364], respectively; P < .0001) and calcifications ( 2D two-dimensional + 3D three-dimensional vs 2D two-dimensional , 2.4% [205 of 8591] vs 3.2% [297 of 9364], respectively; P = .0014). For patients with masses and architectural distortion, the difference in recall rates was not significant (masses: 2D two-dimensional + 3D three-dimensional vs 2D two-dimensional , 2.5% [215 of 8591] vs 2.5% [237 of 9364], respectively; P = .90; architectural distortion: 2D two-dimensional + 3D three-dimensional vs 2D two-dimensional , 0.68% [58 of 8591] vs 0.69% [65 of 9364]; P = .88). Cancer detection was highest in the 2D two-dimensional + 3D three-dimensional group at 5.9 cancers per 1000 examinations, with 5.7 cancers per 1000 examinations in the concurrent 2D two-dimensional group, and 4.4 cancers per 1000 examinations in the historic control.
CONCLUSION: Use of tomosynthesis ( 2D two-dimensional + 3D three-dimensional ) compared with conventional mammography ( 2D two-dimensional ) is associated with a lower recall rate of screening mammography, most often for asymmetries.

Entities:  

Mesh:

Year:  2014        PMID: 25188431     DOI: 10.1148/radiol.14131319

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  34 in total

1.  Digital Breast Tomosynthesis: State of the Art.

Authors:  Srinivasan Vedantham; Andrew Karellas; Gopal R Vijayaraghavan; Daniel B Kopans
Journal:  Radiology       Date:  2015-12       Impact factor: 11.105

2.  Comparison of digital mammography and digital breast tomosynthesis in the detection of architectural distortion.

Authors:  Elizabeth H Dibble; Ana P Lourenco; Grayson L Baird; Robert C Ward; A Stanley Maynard; Martha B Mainiero
Journal:  Eur Radiol       Date:  2017-07-14       Impact factor: 5.315

3.  BI-RADS Category 3 Comparison: Probably Benign Category after Recall from Screening before and after Implementation of Digital Breast Tomosynthesis.

Authors:  Elizabeth S McDonald; Anne Marie McCarthy; Susan P Weinstein; Mitchell D Schnall; Emily F Conant
Journal:  Radiology       Date:  2017-07-17       Impact factor: 11.105

4.  Synthesizing mammogram from digital breast tomosynthesis.

Authors:  Jun Wei; Heang-Ping Chan; Mark A Helvie; Marilyn A Roubidoux; Colleen H Neal; Yao Lu; Lubomir M Hadjiiski; Chuan Zhou
Journal:  Phys Med Biol       Date:  2019-02-11       Impact factor: 3.609

Review 5.  Digital Breast Tomosynthesis: Concepts and Clinical Practice.

Authors:  Alice Chong; Susan P Weinstein; Elizabeth S McDonald; Emily F Conant
Journal:  Radiology       Date:  2019-05-14       Impact factor: 11.105

6.  Masses in the era of screening tomosynthesis: Is diagnostic ultrasound sufficient?

Authors:  Sadia Choudhery; Jessica Axmacher; Amy Lynn Conners; Jennifer Geske; Kathy Brandt
Journal:  Br J Radiol       Date:  2018-12-17       Impact factor: 3.039

7.  Assessment of disease extent on contrast-enhanced MRI in breast cancer detected at digital breast tomosynthesis versus digital mammography alone.

Authors:  A V Chudgar; E F Conant; S P Weinstein; B M Keller; M Synnestvedt; P Yamartino; E S McDonald
Journal:  Clin Radiol       Date:  2017-03-17       Impact factor: 2.350

Review 8.  Applications of Advanced Breast Imaging Modalities.

Authors:  Arwa A Alzaghal; Pamela J DiPiro
Journal:  Curr Oncol Rep       Date:  2018-05-29       Impact factor: 5.075

9.  Characteristics of screen-detected cancers following concordant or discordant recalls at blinded double reading in biennial digital screening mammography.

Authors:  Angela M P Coolen; Joost R C Lameijer; Adri C Voogd; Marieke W J Louwman; Luc J Strobbe; Vivianne C G Tjan-Heijnen; Lucien E M Duijm
Journal:  Eur Radiol       Date:  2018-06-25       Impact factor: 5.315

10.  Technical evaluation of image quality in synthetic mammograms obtained from 15° and 40° digital breast tomosynthesis in a commercial system: a quantitative comparison.

Authors:  Patrizio Barca; Rocco Lamastra; Raffaele Maria Tucciariello; Antonio Traino; Carolina Marini; Giacomo Aringhieri; Davide Caramella; Maria Evelina Fantacci
Journal:  Phys Eng Sci Med       Date:  2020-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.